Covid-19 living Data

Pharmacologic treatments for covid-19 patients

Analyses are updated every two weeks

Methods

Treatment comparisons

Create and download your forest plots with the most up-to-date data here Forest plots

Display new or updated analyses

Display all results

Access the forest plots for the 292 treatment comparisons .

Anti-virals (86 comparisons) update new

Other antimicrobials (antibiotics, antimalarials, antiparasitics) (66 comparisons) update new

NSAIDs and Anti-inflammatories (9 comparisons) update new

Kinase inhibitor (15 comparisons) update new

Corticosteroids (16 comparisons) update new

Monoclonal antibodies (58 comparisons) update new

Immunosupressant (3 comparisons) update new

Convalescent plasma (3 comparisons) update new

Antithrombotic (antiplatelet, anticoagulant, thrombolytic drug) (14 comparisons) update new

Other Advanced therapy medicinal products (ATMP) (8 comparisons) update new

Others (81 comparisons) update new

General characteristics of primary studies

Sort by: Most recent studiesFirst Author
Go to page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40

Page: 1 / Sorted by: Most recent ↓
Trial	Funding	Comparisons		Design	Participants	Sample size	Overall risk of bias Highest assessment	Full description
		Treatment 1	Treatment 2
New ChiCTR2000029972 Huang L, medRxiv (2021) Full text Commentary Commentary	Public/non profit	SWD	Standard care	RCT	Patients with confirmed COVID-19 (mild-moderate) admitted to a single center in China	N=50	Some concerns Details	Full description
New PACTR202108891693522 Babalola O, J Infect Dis Epidemi (2021) Full text Commentary Commentary Commentary	Public/non profit	Hydroxychloroquine+iverme	Ivermectin	RCT	Patients with confirmed COVID-19 (mild-critical) admitted to a single center in Nigeria.	N=61	High Details	Full description
New NCT04397757 PennCCP2 Bar KJ, J Clin Invest (2021) Full text Commentary	Public/non profit	Convalescent plasma	Standard care	RCT	Patients with confirmed COVID-19 (mild-severe) admitted to 2 centers in the USA.	N=80	Some concerns Details	Full description
New NCT04518410 ACTIV-2/A5401 Chew K (B), medRxiv (2021) Full text Commentary Commentary	Mixed	Bamlanivimab 700 mg	Placebo	RCT	Outpatients with confirmed COVID-19 (mild) treated at 38 centers in the USA	N=222	Some concerns Details	Full description
New CTRI/2020/09/027535 Ramachandran R, Int. J. Infect. Dis. (2021) Full text 00872-9/fulltext Commentary	Public/non profit	Umifenovir	Standard care	RCT	In- and outpatients with confirmed COVID-19 (asymptomatic-mild-moderate) treated or admitted by 3 centers in India	N=132	Some concerns Details	Full description
New IRCT20120703010178N20 Kharazmi AB, Immun Inflamm Dis (2021) Full text Commentary	Private	Anakinra	Standard care	RCT	Patients with confirmed COVID-19 (moderate-critical) admitted to a single center in Iran.	N=30	High Details	Full description
New NCT04518410 ACTIV-2/A5401 Chew K (A), medRxiv (2021) Full text Commentary Commentary	Mixed	Bamlanivimab 7000 mg	Placebo	RCT	Outpatients with confirmed COVID-19 (mild) treated at 38 centers in the USA	N=97	Some concerns Details	Full description
NCT04435184 Leucker T, JACC (2021) Full text Commentary	Private	Crizanlizumab	Placebo	RCT	Patients with confirmed COVID-19 (mild-moderate) admitted to 3 centers in the USA	N=54	Some concerns Details	Full description
NCT04501978 ACTIV-3 Self WH, Lancet Infect Dis (2021) Full text Commentary (21)00762-3/fulltext Commentary	Mixed	Sotrovimab BRII-196/BRII-198 Sotrovimab	Placebo Placebo BRII-196/BRII-198	RCT	Patients with confirmed COVID-19 (mild-moderate) admitted to 43 centres in Denmark, Poland, Switzerland, and USA	N=546	Low Details	Full description
NCT04501952; EudraCT 2020-003510-12. Gottlieb RL, N Engl J Med (2021) Full text Commentary Commentary	Private	Remdesivir	Placebo	RCT	Outpatients with confirmed COVID-19 (mild) treated at 64 centers in Denmark, Spain, UK and USA.	N=584	Some concerns Details	Full description